comprehensive -WSS

comprehensive

author：comprehensive 2025-08-22 15:48:33 - browse：23241

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： ACIP vaccine advisory panel sees its vacancies filled

WSS

Congress considering partial increase for doctor pay in Medicare

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress might make insulin pumps more accessible to the blind

RSV shot was 90% effective at preventing hospitalizations in kids

Congress might make insulin pumps more accessible to the blind

Change Healthcare cyberattack prompts Medicare loan program

Wikipedia

comprehensive

leisure time

In Memoriam: Notable people who died in 2023

Headspace, Meta partner to launch VR meditation app for Quest

The high cost of giving birth even with insurance

The drug industry has found itself all alone in Washington

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Hepatitis C has a cure — but many Americans still lack access to it

Ebola vaccine can save some who are already sick, per new study

In Memoriam: Notable people who died in 2023

Just how do doctors, lawmakers, and the public define abortion?

knowledge

First medicine developed to treat MASH expected to be approved soon

ACIP vaccine advisory panel sees its vacancies filled

Too many hospitalized Covid

Too many hospitalized Covid

RSV shot was 90% effective at preventing hospitalizations in kids

Doctors on social media are being harassed and cyberbullied

hotspot

Wikipedia

focus

focus